Novo Nordisk A/S (CPH:NOVO.B)
452.10
+5.05 (1.13%)
Jul 25, 2025, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B
Revenue Growth
+24.11%
P/S Ratio
6.62
Revenue / Employee
3.92M
Employees
77,349
Market Cap
2,006.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coloplast | 27.79B |
Genmab | 22.30B |
Demant | 22.42B |
ALK-Abelló | 5.71B |
H. Lundbeck | 22.95B |
Ambu A/S | 5.83B |
Zealand Pharma | 55.69M |
Bavarian Nordic | 6.23B |
Novo Nordisk News
- 1 day ago - Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China - Benzinga
- 1 day ago - 3 'Wide Moat' SWANs - Seeking Alpha
- 1 day ago - Novo Nordisk gets EU recommendation to update Alhemo label - Seeking Alpha
- 1 day ago - European regulatory authority adopts positive opinion for Novo Nordisk's Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors - GlobeNewsWire
- 2 days ago - Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years - Benzinga
- 2 days ago - Novo Nordisk: Undervalued Despite Strong Growth Trend And Solid Market Share - Seeking Alpha
- 2 days ago - This Weight-Loss Stock Sank After Earnings. It's Still a Risk for Eli Lilly, Novo Nordisk. - Barrons
- 3 days ago - What's Going On With Hims & Hers Stock Wednesday? - Benzinga